- Home
- VYGR vs BSL Comparison
VYGR vs BSL Comparison
Compare VYGR & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- BSL
- Stock Information
- Founded
- VYGR 2013
- BSL 2010
- Country
- VYGR United States
- BSL United States
- Employees
- VYGR N/A
- BSL N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- BSL Trusts Except Educational Religious and Charitable
- Sector
- VYGR Health Care
- BSL Finance
- Exchange
- VYGR Nasdaq
- BSL Nasdaq
- Market Cap
- VYGR 156.0M
- BSL 184.9M
- IPO Year
- VYGR 2015
- BSL N/A
- Fundamental
- Price
- VYGR $2.97
- BSL $14.18
- Analyst Decision
- VYGR Strong Buy
- BSL
- Analyst Count
- VYGR 8
- BSL 0
- Target Price
- VYGR $14.33
- BSL N/A
- AVG Volume (30 Days)
- VYGR 841.7K
- BSL 71.9K
- Earning Date
- VYGR 08-05-2025
- BSL 01-01-0001
- Dividend Yield
- VYGR N/A
- BSL 9.55%
- EPS Growth
- VYGR N/A
- BSL N/A
- EPS
- VYGR N/A
- BSL N/A
- Revenue
- VYGR $66,958,000.00
- BSL N/A
- Revenue This Year
- VYGR N/A
- BSL N/A
- Revenue Next Year
- VYGR $78.88
- BSL N/A
- P/E Ratio
- VYGR N/A
- BSL N/A
- Revenue Growth
- VYGR N/A
- BSL N/A
- 52 Week Low
- VYGR $2.65
- BSL $12.19
- 52 Week High
- VYGR $9.55
- BSL $14.56
- Technical
- Relative Strength Index (RSI)
- VYGR 41.86
- BSL 53.78
- Support Level
- VYGR $3.24
- BSL $14.14
- Resistance Level
- VYGR $3.64
- BSL $14.25
- Average True Range (ATR)
- VYGR 0.27
- BSL 0.09
- MACD
- VYGR -0.02
- BSL -0.00
- Stochastic Oscillator
- VYGR 6.17
- BSL 58.82
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About BSL Blackstone
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.